The U.S. growth acceleration to 13% (from ~1.5% last quarter) confirms the MiniMed Flex launch is driving a step-change in domestic market share. With guidance raised and a strong pipeline (MiniMed Fit, Vivera FCL, extended-wear sensor), the stock should re-rate higher. Monitor Q2 for sustained U.S. NPS growth and CGM attachment rate progression above 70%.
Price Chart
Executive Summary
MiniMed reported Q1 FY27 net sales of $843M (+16.6% YoY as reported, +15.8% organic), with U.S. growth accelerating to 13.1% and international up 18.1%. The company raised FY27 organic revenue growth guidance to ~10.5% from ~10%, while reaffirming ~16% adjusted EBITDA margin. GAAP EPS was $0.00, essentially breakeven vs a loss of -$0.08 a year ago, but this is a medical device company where the Street focuses on revenue growth and pipeline catalysts, not GAAP EPS.
Key Financial Metrics
Key Facts
- Worldwide net sales of $843M grew 16.6% as reported and 15.8% organic
- U.S. net sales grew 13.1% YoY, accelerating from 1.5% in Q4 FY26, driven by MiniMed Flex launch
- U.S. New Pumps Sold grew over 20% YoY
- FY27 organic revenue growth guidance raised to ~10.5% from ~10%
- MiniMed Fit patch pump submitted to FDA; MiniMed Flex received CE Mark; Vivera FCL pivotal trial enrollment complete
- GAAP net income attributable to the Company was approximately $0 (breakeven) vs a loss of $19M in the prior year period
- GAAP EPS was $0.00 vs -$0.08 in Q1 FY26
Financial Impact
Q1 net sales of $843M, up 16.6% YoY; FY27 organic revenue guidance raised to ~10.5%
Risk Factors
- GAAP profitability remains near zero; adjusted EBITDA margin guidance of ~16% leaves limited margin of safety if growth decelerates
- Extra week benefit (~4-6%) in Q1 will not repeat in subsequent quarters
- Competitive pressure from Dexcom G7 and Tandem Mobi could slow U.S. market share gains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-059699 |
| Document: mmed-20260901.htm | 0001628280-26-059699 |
| Document: 0001628280-26-059699-index-headers.html | 0001628280-26-059699 |
| Document: 0001628280-26-059699-index.html | 0001628280-26-059699 |
| Document: 0001628280-26-059699.txt | 0001628280-26-059699 |
| 8-K Data (Synthetic) | 0001628280-26-059699 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 14, 2026 18d ago | S-4 / 425 | $21.97 $21.12 | ▼ −3.87% | ▼ −3.98% | $19.56 (−10.97%) |
Sep 1, 2026 4w ago | 8-K | $22.42 $22.76 | ▲ +1.52% | ▲ +1.44% | $19.56 (−12.76%) |
Jul 6, 2026 12w ago | 3 | $15.37 $15.04 | ▼ −2.15% | ▼ −2.70% | $19.56 (+27.26%) |
Jun 29, 2026 13w ago | 8-K | $14.88 $15.29 | ▲ +2.76% | ▲ +1.37% | $19.56 (+31.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access